Veterinary Medicines

HIPRABOVIS-4

Authorised
  • Bovine herpesvirus 1, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Download as PDF

Product identification

Medicine name:
HIPRABOVIS-4
Active substance:
  • Bovine herpesvirus 1, strain LA, Inactivated
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
  • Bovine respiratory syncytial virus, strain Lym-56, Live
Target species:
  • Cattle
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Bovine herpesvirus 1, strain LA, Inactivated
    39810700.00
    50% tissue culture infectious dose
    /
    3.00
    millilitre(s)
  • Bovine parainfluenza virus 3, strain SF-4, Inactivated
    500.00
    haemagglutinating units
    /
    3.00
    millilitre(s)
  • Bovine viral diarrhoea virus, strain NADL, Inactivated
    3981070.00
    50% tissue culture infectious dose
    /
    3.00
    millilitre(s)
  • Bovine respiratory syncytial virus, strain Lym-56, Live
    1995260.00
    50% tissue culture infectious dose
    /
    3.00
    millilitre(s)
Pharmaceutical form:
  • Powder and solvent for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AH
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • Freeze-dried fraction: the container is composed by neutral colourless glass flasks of 10 ml (30 doses) classified as TypeI (Eur. Phar.), grey elastomer Type I closures (Eur. Phar.) and detachable aluminium caps.Liquid fraction: the container is composed by coloured glass flasks of 100 ml (30 doses) Type II (Eur. Phar.), grey elastomer Type II closures (Eur. Phar.) and capsules made of anodised aluminium.
  • Freeze-dried fraction: the container is composed by neutral colourless glass flasks of 10 ml (5 doses) classified as TypeI (Eur. Phar.), grey elastomer Type I closures (Eur. Phar.) and detachable aluminium caps.Liquid fraction: the container is composed by coloured glass flasks of 20 ml (5 doses) Type I (Eur. Phar.), grey elastomer Type II closures (Eur. Phar.) and capsules made of anodised aluminium.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • Health Products Regulatory Authority
Authorisation number:
  • VPA10846/003/001
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download